Activation of Epstein-Barr virus by 5-bromodeoxyuridine in "virus-free" human cells (complement-fixing antigen-immunofluorescence-leukocytes).
Treatment of three human lymphoid cell lines, free of detectable Epstein-Barr virus, with 5-bromodeoxyuridine resulted in activation of virus synthesis in up to 8% of the cells. The induction of infectious virus could be demonstrated by cocultivation experiments with peripheral leukocytes. These studies demonstrated that the entire viral genome may persist in at least a portion of the lymphoid cells.
D000937:Antigen-Antibody Reactions; D000956:Antigens, Viral; D001973:Bromodeoxyuridine / Q000494:pharmacology*; D002460:Cell Line; D003168:Complement Fixation Tests; D003470:Culture Media; D005455:Fluorescent Antibody Technique; D006564:Herpesviridae / Q000187:drug effects*; D006801:Humans; D007106:Immune Sera; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D014779:Virus Replication / Q000187:drug effects
D000956:Antigens, Viral; D003470:Culture Media; D007106:Immune Sera; D001973:Bromodeoxyuridine